CA-ARMIS
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Top Performer in the 2024 Best in KLAS Software & Services Report for Healthcare IoT Security for the second year in a row. The Best in KLAS report recognizes software and services companies that excel in helping healthcare professionals improve patient care.
“This recognition from KLAS which is based solely on customer reviews is a true testament to our ongoing commitment to protecting the attack surfaces of healthcare organizations,” said Mohammad Waqas, CTO of Healthcare at Armis. “I want to thank every Armis customer who took the time this year to share with KLAS their experience with Armis CentrixTM for Medical Device Security. Your feedback is instrumental in helping us continuously improve our solutions and deliver the best possible value to the healthcare community.”
The 2024 Best in KLAS report, based on independent feedback from healthcare providers in North America, evaluates vendors across six key performance areas: culture, loyalty, operations, product, relationship and value. Armis achieved an outstanding overall score, demonstrating excellence in every category and solidifying the company’s position as a leader in Healthcare IoT Security.
When asked about Armis, customers shared the following anonymized comments with KLAS in review of the company’s solution:
- “Given the nature of how sensitive and aware we have all become to some of the hazards surrounding cybersecurity and cyber risks associated with penetration into personal health information through many different avenues of medical devices and applications, the Armis application is robust in being able to see all network-connected devices. It is really incredible to see the amount of horsepower that the Armis platform brings to the table for us. The product really is a great tool. Not only can the reporting piece identify connected devices but it is able to identify what type of device something is through the product's algorithms. The product is able to determine what the make, model, and serial number are, and in some cases, what operating system the device is functioning on. Recently, we had an issue with updating the security on anything that was still running on something other than Windows 10, and through the Armis system, we were able to see how many devices were reporting through the application that were not up to Windows 10. With the reporting structure, we now have a line of sight into many things we didn't know about.” - Director, April 2023
- “Armis does very well with implementations. They are very knowledgeable about their products. They have experts on their team, so if we need some help with a configuration, they have resources available that are on standby typically to help and engage in troubleshooting.” - Analyst/Coordinator, April 2023
- “In general, Armis regularly updates their platform and gives good notifications about new enhancements and new features. They back those notifications up with written material and videos, as well as live sessions if we are lucky enough to find the time to attend them. It is good that the vendor is constantly adding new features and new capabilities to the product.” - Analyst/Coordinator, September 2023
In July 2023, Armis was rated the best-performing cross-industry vendor in the KLAS Healthcare IoT Security 2023 report for its deep coverage of IoT, OT, IoMT and IT across all verticals.
In the past year, Armis has continued to deepen its commitment to securing healthcare organizations. Combining the power of Armis CentrixTM, the cyber exposure management platform, and the Armis AI-powered Asset Intelligence Engine, Armis has reinforced its healthcare-specific capabilities which help to provide complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem with zero disruptions to patient care.
Armis is a sponsor of HIMSS 2024, taking place in Orlando, FL March 11-15. Stop by Armis’ booth #1621 in the CyberSecurity Command Center or visit the team in the Main Walkway at booth #1048. At HIMSS, Armis’ CTO of Healthcare, Mohammad Waqas, will speak to “Building a Comprehensive Healthcare Security Program for Next-Gen Patient Care.” This session will be held on Tuesday, March 12th from 10:15am - 10:30am EDT in the Orange County Convention Center, Theatre A.
To read the KLAS report, please visit: 2024 Best in KLAS - Software & Services
To learn more about Armis CentrixTM for Medical Device Security, go to: https://www.armis.com/platform/armis-centrix-for-medical-device-security/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
About KLAS Research
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212843101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release
Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
